SCHEMBL22190871

SCHEMBL22190871

CC(C)n1c(=O)c(-c2ccc(N)c(F)c2)nc2cnc(N[C@H]3C[C@H](F)CN(C(=O)O)C3)nc21

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.50
MAPK8 P45983 11/20 0.37
MAPK10 P53779 10/20 0.37
MAPK9 P45984 8/20 0.37
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
CCND3 P30281 1/20 0.37
CDK6 Q00534 1/20 0.37
KDM5B Q9UGL1 1/20 0.35
CCNA2 P20248 3/20 0.35
CDK2 P24941 3/20 0.35
CDK7 P50613 3/20 0.35
CCNH P51946 3/20 0.35
MNAT1 P51948 3/20 0.35
CCNK O75909 2/20 0.35
CDK12 Q9NYV4 2/20 0.35
USP2 O75604 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22190873 0.92 ERN1 (0.47) ERN1MAPK8MAPK10MAPK9CDK4
SCHEMBL22191044 0.91 ERN1 (0.46) ERN1MAPK8MAPK10MAPK9CDK4
SCHEMBL22200708 0.90 ERN1 (0.47) ERN1MAPK8MAPK10MAPK9CDK4
SCHEMBL29356368 0.90 ERN1 (0.47) ERN1MAPK8MAPK10MAPK9CDK4
SCHEMBL22191106 0.89 ERN1 (0.45) ERN1MAPK8MAPK10MAPK9CDK4
SCHEMBL22191004 0.89 ERN1 (0.44) ERN1MAPK8MAPK10MAPK9CCNA2
SCHEMBL22200705 0.89 ERN1 (0.48) ERN1MAPK8CDK4CCND1CDK2
SCHEMBL29356760 0.89 ERN1 (0.48) ERN1MAPK8CDK4CCND1CDK2
SCHEMBL22191082 0.85 ERN1 (0.56) ERN1MAPK8MAPK10MAPK9CDK4
SCHEMBL22191075 0.84 ERN1 (0.55) ERN1MAPK8MAPK10MAPK9CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE PARAZA PHARMA, INC. (CA) 2023-02-16 US disclosed
EP-3941919-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES Genentech, Inc. (US) 2022-01-26 EP disclosed
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047209-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE TYMP, TYMS, DPYD ERN1 3167/4885MAPK8 925/4885MAPK10 3731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.